These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 9011785)

  • 1. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group.
    Johannesson M; Jönsson B; Kjekshus J; Olsson AG; Pedersen TR; Wedel H
    N Engl J Med; 1997 Jan; 336(5):332-6. PubMed ID: 9011785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The Scandinavian Simvastatin Survival Study: the clinical consequences].
    Larsen ML
    Rev Esp Cardiol; 1995; 48 Suppl 5():39-42. PubMed ID: 7494939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cost-effectiveness of lowering of blood cholesterol using simvastatin and cholestyramine].
    Martens LL; Rutten FF; Kuijpens JL; Winter J
    Ned Tijdschr Geneeskd; 1991 Apr; 135(15):655-9. PubMed ID: 1903849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors for a major coronary event after myocardial infarction in the Scandinavian Simvastatin Survival Study (4S). Impact of predicted risk on the benefit of cholesterol-lowering treatment.
    Wilhelmsen L; Pyörälä K; Wedel H; Cook T; Pedersen T; Kjekshus J
    Eur Heart J; 2001 Jul; 22(13):1119-27. PubMed ID: 11428852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of simvastatin in the secondary prevention of coronary artery disease in Canada.
    Rivière M; Wang S; Leclerc C; Fitzsimon C; Tretiak R
    CMAJ; 1997 Apr; 156(7):991-7. PubMed ID: 9099167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. At what coronary risk level is it cost-effective to initiate cholesterol lowering drug treatment in primary prevention?
    Johannesson M
    Eur Heart J; 2001 Jun; 22(11):919-25. PubMed ID: 11428815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Data on cholesterol level screening of patients with ischemic heart disease in the light of the Scandinavian Simvastatin Survival Study].
    Márk L; Kondacs A; Hanyecz V; Simondán G
    Orv Hetil; 1997 Jun; 138(26):1679-82. PubMed ID: 9289681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study.
    Pedersen TR; Berg K; Cook TJ; Faergeman O; Haghfelt T; Kjekshus J; Miettinen T; Musliner TA; Olsson AG; Pyörälä K; Thorgeirsson G; Tobert JA; Wedel H; Wilhelmsen L
    Arch Intern Med; 1996 Oct; 156(18):2085-92. PubMed ID: 8862101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S).
    Jönsson B; Johannesson M; Kjekshus J; Olsson AG; Pedersen TR; Wedel H
    Eur Heart J; 1996 Jul; 17(7):1001-7. PubMed ID: 8809516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of dietary treatment of hypercholesterolemia in Spain.
    Rubió PP
    Public Health; 1997 Jan; 111(1):33-40. PubMed ID: 9033222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Which statin is most efficient for the treatment of hypercholesterolemia? A cost-effectiveness analysis.
    Cobos A; Jovell AJ; García-Altés A; García-Closas R; Serra-Majem L
    Clin Ther; 1999 Nov; 21(11):1924-36. PubMed ID: 10890264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost effectiveness of cholesterol-lowering drugs: a review of the evidence.
    Thorvik E; Aursnes I; Kristiansen IS; Waaler HT
    Wien Klin Wochenschr; 1996; 108(8):234-43. PubMed ID: 8686314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cholesterol-lowering therapy after heart transplantation: a 12-month randomized trial.
    Pflugfelder PW; Huff M; Oskalns R; Rudas L; Kostuk WJ
    J Heart Lung Transplant; 1995; 14(4):613-22. PubMed ID: 7578166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cost-effectiveness of pharmacologic treatments for the reduction of blood lipids].
    Plans Rubió P; Rovira Forns J
    Med Clin (Barc); 1995 Sep; 105(9):327-33. PubMed ID: 7500685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women.
    Darling GM; Johns JA; McCloud PI; Davis SR
    N Engl J Med; 1997 Aug; 337(9):595-601. PubMed ID: 9271481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Therapy and prevention of coronary heart diseases through lowering of the serum cholesterol levels; third consensus 'Cholesterol'. Consensus Working Group, CBO].
    Simoons ML; Casparie AF
    Ned Tijdschr Geneeskd; 1998 Sep; 142(38):2096-101. PubMed ID: 9856223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease. Estimating the benefits of increasing HDL-C.
    Hamilton VH; Racicot FE; Zowall H; Coupal L; Grover SA
    JAMA; 1995 Apr; 273(13):1032-8. PubMed ID: 7897787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cost effectiveness in the Danish health care of ezetemibe co-administration compared to simvastatin].
    Keiding H; Hildebrandt P; Alemao E; Davies GM
    Ugeskr Laeger; 2008 Jun; 170(26-32):2323-6. PubMed ID: 18570764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease.
    Martens LL; Guibert R
    Clin Ther; 1994; 16(6):1052-62; discussion 1036. PubMed ID: 7697684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels.
    Tsevat J; Kuntz KM; Orav EJ; Weinstein MC; Sacks FM; Goldman L
    Am Heart J; 2001 May; 141(5):727-34. PubMed ID: 11320359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.